% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • naked_finger naked_finger Dec 18, 2012 6:50 PM Flag

    Valuation: Buying opportunity

    With an EV of only $142m, we believe the market is significantly underestimating the
    potential of vintafolide in ovarian cancer, other indications (lung cancer, Phase IIb
    data in H114), or the value of the Merck licensing deal (potential for additional
    indications). Moreover, given Endocyte’s modest EV and low investor expectations,
    EU conditional approval for vintafolide in H213 could offer significant upside.

    Sentiment: Strong Buy

11.0536+0.0736(+0.67%)12:46 PMEDT